Michael L Akers

US Patent:

20120214199, Aug 23, 2012

Filed:

Feb 23, 2011

Appl. No.:

13/032814

Inventors:

Ronald E. Zimmerman - Greenwood IN, US
David John Stokell - Indianapolis IN, US
Michael Patrick Akers - Indianapolis IN, US

Assignee:

Elona Biotechnologies - Greenwood IN

International Classification:

C07K 14/62
C12P 21/06
C12N 1/21
C12P 21/02
C12N 15/63
C12N 1/00

US Classification:

435 681, 530303, 4353201, 435243, 43525233, 435 694

Abstract:

Lis-Pro modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification are presented. Methods for producing Lis-Pro insulin analogs are also disclosed. Highly efficient processes for preparing the Lis-Pro insulin analogs and improved preparations containing the Lis-Pro insulin analogs prepared according to the methods described herein are also provided.

US Patent:

20120214963, Aug 23, 2012

Filed:

Feb 23, 2011

Appl. No.:

13/032775

Inventors:

Ronald E. Zimmerman - Greenwood IN, US
David John Stokell - Indianapolis IN, US
Michael Patrick Akers - Indianapolis IN, US

Assignee:

Elona Biotechnologies - Greenwood IN

International Classification:

C07K 14/62
C12N 1/21
C12P 21/02
C12N 15/63

US Classification:

530303, 4353201, 43525233, 435 694

Abstract:

Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.

US Patent:

20120214964, Aug 23, 2012

Filed:

Feb 23, 2011

Appl. No.:

13/032797

Inventors:

Ronald E. Zimmerman - Greenwood IN, US
David John Stokell - Indianapolis IN, US
Michael Patrick Akers - Indianapolis IN, US

Assignee:

Elona Biotechnologies - Greenwood IN

International Classification:

C07K 14/62
C12P 21/06
C12N 15/63
C12N 1/21

US Classification:

530303, 43525233, 435 681, 4353201

Abstract:

Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharmaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed cell banks (WCB) capable of expressing the recombinant human insulin are also provided.

US Patent:

20120214965, Aug 23, 2012

Filed:

Feb 23, 2011

Appl. No.:

13/032806

Inventors:

Ronald E. Zimmerman - Greenwood IN, US
David John Stokell - Indianapolis IN, US
Michael Patrick Akers - Indianapolis IN, US

Assignee:

Elona Biotechnologies - Greenwood IN

International Classification:

C07K 14/62
C12N 1/21
C12P 21/02
C12N 15/63

US Classification:

530303, 4353201, 43525233, 435 694

Abstract:

Glargine proinsulin sconstructs that have a modified C-peptide amino acid and/or nucleic acid sequence for producing glargine insulin analogs are provided. Highly efficient processes for preparing the glargine insulin analogs and improved preparations containing the glargine insulin analogs prepared according to the methods described herein are also provided.

US Patent:

20130210716, Aug 15, 2013

Filed:

Apr 17, 2013

Appl. No.:

13/864955

Inventors:

HORIZON BANK NA - , US
David J. Stokell - Indianapolis IN, US
Michael P. Akers - Indianapolis IN, US

Assignee:

HORIZON BANK NA - FRANKLIN IN

International Classification:

C07K 14/62

US Classification:

514 59, 4353201, 43525233, 435 691, 435 681

Abstract:

Lis-Pro modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification are presented. Methods for producing Lis-Pro insulin analogs are also disclosed. Highly efficient processes for preparing the Lis-Pro insulin analogs and improved preparations containing the Lis-Pro insulin analogs prepared according to the methods described herein are also provided.

US Patent:

45347581, Aug 13, 1985

Filed:

Jul 15, 1983

Appl. No.:

6/514268

Inventors:

Michael J. Akers - Greenwood IN
William W. Hargrove - Indianapolis IN
Dale C. Harris - Fairland IN
Charles R. Sperry - Westport CT

Assignee:

Eli Lilly & Company - Indianapolis IN

International Classification:

A61M 514

US Classification:

604 85

Abstract:

Valved adaptors are disclosed permitting the introduction of a drug-containing vial in the delivery tube of an I. V. administration set. The adaptors have a three position operation characterized by a bypass mode, a dilution mode, and a delivery mode, the adaptors being manually changed from mode to mode. The disclosed adaptors include gravity operated valves, reciprocating spool valves, and rotating spool valves, each including a spike to penetrate the stopper of a vial and a vent to permit air to escape the vial as liquid is introduced to dilute the vial contents.

US Patent:

45739676, Mar 4, 1986

Filed:

Dec 6, 1983

Appl. No.:

6/558060

Inventors:

William W. Hargrove - Indianapolis IN
Dale C. Harris - Fairland IN
Michael J. Akers - Greenwood IN
Charles R. Sperry - Westport CT

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61W 500

US Classification:

604 56

Abstract:

An apparatus for connecting a vial into the delivery tube of an intravenous administration set, the set including a container of fluid connected to one end of a delivery tube with the other end of the delivery tube adapted for insertion into the patient. The apparatus includes a penetrating spike penetrating an end of the vial which provides two pathways into the interior of the vial with two sections of the delivery tube connected to the two pathways of the penetrating spike. The apparatus also includes a frame for maintaining the two sections of the delivery tube adjacent to each other and clamp for releasably closing the adjacent sections of the delivery tube to temporarily prevent flow of fluid through the penetrating spike.

US Patent:

20160289291, Oct 6, 2016

Filed:

Jan 27, 2016

Appl. No.:

15/007949

Inventors:

- Bangalore, IN
David John STOKELL - Indianapolis IN, US
Michael Patrick AKERS - Indianapolis IN, US

International Classification:

C07K 14/62
C12N 15/70
C12P 21/02

Abstract:

Novel proinsulins and glargine, aspart and Lis-Pro proinsulin analogs having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production, as well as novel and highly efficient processes for preparing the same. The novel proinsulins and proinsulin analogs may be converted into human insulin and insulin analogs, respectively, that are useful in therapeutic preparations.